Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (40)

Sep 2, 2036formulationUS 10188644
Sep 2, 2036formulationUS 10188644
Sep 2, 2036formulationUS 10188644
Sep 2, 2036formulationUS 10188644
Sep 2, 2036formulationUS 10188644
Sep 2, 2036formulationUS 10646485
Sep 2, 2036formulationUS 10646485
Sep 2, 2036formulationUS 10646485
Sep 2, 2036formulationUS 10646485
Sep 2, 2036formulationUS 10646485
Sep 2, 2036formulationUS 9737530
Sep 2, 2036formulationUS 9737530
Sep 2, 2036formulationUS 9737530
Sep 2, 2036formulationUS 9737530
Sep 2, 2036formulationUS 9737530
Sep 2, 2036formulationUS 9968598
Sep 2, 2036formulationUS 9968598
Sep 2, 2036formulationUS 9968598
Sep 2, 2036formulationUS 9968598
Sep 2, 2036formulationUS 9968598
Dec 10, 2030formulationUS 100047294.3y
Dec 10, 2030formulationUS 100047294.3y
Dec 10, 2030formulationUS 100047294.3y
Dec 10, 2030formulationUS 100047294.3y
Dec 10, 2030formulationUS 100047294.3y
Dec 10, 2030formulationUS 106680604.3y
Dec 10, 2030formulationUS 106680604.3y
Dec 10, 2030formulationUS 106680604.3y
Dec 10, 2030formulationUS 106680604.3y
Dec 10, 2030formulationUS 106680604.3y
Dec 10, 2030formulationUS 96820754.3y
Dec 10, 2030formulationUS 96820754.3y
Dec 10, 2030formulationUS 96820754.3y
Dec 10, 2030formulationUS 96820754.3y
Dec 10, 2030formulationUS 96820754.3y
Oct 9, 2028formulationUS 77717072.1y
Oct 9, 2028formulationUS 77717072.1y
Oct 9, 2028formulationUS 77717072.1y
Oct 9, 2028formulationUS 77717072.1y
Oct 9, 2028formulationUS 77717072.1y

News(2)

STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the market
stat · 22d ago
Super-potent synthetic opioids called nitazenes are spreading across the U.S.
Overdose deaths confirmed to involve nitazenes have risen sharply in the U.S., from 27 in 2020 to 409 in 2024, according to the CDC
stat · 2mo ago

brand

Xtampza ER

generic

oxycodone

MOA

12.1 Mechanism of Action Oxycodone is a full opioid agonist and is relatively selective for the mu receptor, although it can bind to other opioid receptors at higher doses. The principal therapeutic action of oxycodone is analgesia. Like all full opioid agonists, there is no ceiling effect to analgesia for oxycodone. Clinically, dosage is titrated to provide adequate analgesia and may be limited by adverse reactions, including respiratory and CNS depression. The precise mechanism of the analgesic action is unknown. However, specific CNS opioid receptors for endogenous compounds with opioid-like activity have been identified throughout the brain and spinal cord and are thought to play a role in the analgesic effects of this drug. In addition, when oxycodone binds to mu-opioid receptors, it results in positive subjective effects, such as drug liking, euphoria, and high.

indication

Pain

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 19m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug

save

oxycodone ER

Marketedupdated 3mo ago

by $COLL COLLEGIUM PHARMACEUTICAL, INC

Approved

community read0 votes

🐶 often sniffed alongside

top 8

Small molecule drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 30 investigational indications.

all catalysts(13)

approval · 13

XTAMPZA ER (OXYCODONE) — FDA approval

XTAMPZA ER (OXYCODONE) — FDA approval

XTAMPZA ER (OXYCODONE) — FDA approval

XTAMPZA ER (OXYCODONE) — FDA approval

XTAMPZA ER (OXYCODONE) — FDA approval

XTAMPZA ER (OXYCODONE) — FDA approval

XTAMPZA ER (OXYCODONE) — FDA approval

XTAMPZA ER (OXYCODONE) — FDA approval

XTAMPZA ER (OXYCODONE) — FDA approval

XTAMPZA ER (OXYCODONE) — FDA approval

XTAMPZA ER (OXYCODONE) — FDA approval

XTAMPZA ER (OXYCODONE) — FDA approval

XTAMPZA ER (OXYCODONE) — FDA approval

oxycodone ER

→

view all 13 catalysts →

Trials studying oxycodone ER

—Anesthetics and Analgesics in Childrenrecruitingn=500
—Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infantsrecruitingn=1,600
N/AIntercostal Nerve Cryoablation Versus Epidural Analgesia for Nuss Repair of Pectus Excavatumcompletedn=50
phase3A Study of Cebranopadol for the Treatment of Acute Pain After Bunionectomycompletedn=240
phase1A Study to Investigate the Pharmacodynamic Effect of Single Doses of MT-8554 in Healthy Subjectscompletedn=20
phase1Buprenorphine-Fentanyl Interaction Studycompletedn=22
—Impact of Opioid Avoidance Protocol for ACL Reconstructioncompletedn=32
phase3Fixed-dose Combination of Oxycodone [OXIcodona] + IbuproFEN in Pain Relief After Third Molar Extractioncompletedn=288

more trials →

Patent cliff

source: FDA Orange Book

first barrier falls

Oct 9, 2028

~2.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (40)

Sep 2, 2036formulationUS 10188644
Sep 2, 2036formulationUS 10188644
Sep 2, 2036formulationUS 10188644
Sep 2, 2036formulationUS 10188644
Sep 2, 2036formulationUS 10188644
Sep 2, 2036formulationUS 10646485
Sep 2, 2036formulationUS 10646485
Sep 2, 2036formulationUS 10646485
Sep 2, 2036formulationUS 10646485
Sep 2, 2036formulationUS 10646485
Sep 2, 2036formulationUS 9737530
Sep 2, 2036formulationUS 9737530
Sep 2, 2036formulationUS 9737530
Sep 2, 2036formulationUS 9737530
Sep 2, 2036formulationUS 9737530
Sep 2, 2036formulationUS 9968598
Sep 2, 2036formulationUS 9968598
Sep 2, 2036formulationUS 9968598
Sep 2, 2036formulationUS 9968598
Sep 2, 2036formulationUS 9968598
Dec 10, 2030formulationUS 100047294.3y
Dec 10, 2030formulationUS 100047294.3y
Dec 10, 2030formulationUS 100047294.3y
Dec 10, 2030formulationUS 100047294.3y
Dec 10, 2030formulationUS 100047294.3y
Dec 10, 2030formulationUS 106680604.3y
Dec 10, 2030formulationUS 106680604.3y
Dec 10, 2030formulationUS 106680604.3y
Dec 10, 2030formulationUS 106680604.3y
Dec 10, 2030formulationUS 106680604.3y
Dec 10, 2030formulationUS 96820754.3y
Dec 10, 2030formulationUS 96820754.3y
Dec 10, 2030formulationUS 96820754.3y
Dec 10, 2030formulationUS 96820754.3y
Dec 10, 2030formulationUS 96820754.3y
Oct 9, 2028formulationUS 77717072.1y
Oct 9, 2028formulationUS 77717072.1y
Oct 9, 2028formulationUS 77717072.1y
Oct 9, 2028formulationUS 77717072.1y
Oct 9, 2028formulationUS 77717072.1y

News(2)

STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the market
stat · 22d ago
Super-potent synthetic opioids called nitazenes are spreading across the U.S.
Overdose deaths confirmed to involve nitazenes have risen sharply in the U.S., from 27 in 2020 to 409 in 2024, according to the CDC
stat · 2mo ago

brand

Xtampza ER

generic

oxycodone

MOA

indication

Pain

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 19m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

oxycodone ER

🐶 often sniffed alongside

all catalysts(13)

Trials studying oxycodone ER

Patent cliff

patents (40)

News(2)

Report a data issue

comments(0)

oxycodone ER

🐶 often sniffed alongside

all catalysts(13)

Trials studying oxycodone ER

Patent cliff

patents (40)

News(2)

Report a data issue

comments(0)